New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
08:40 EDTALXNAlexion gets positive CHMP opinion on extended indication for eculizumab
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Soliris. The marketing authorization holder for this medicinal product is Alexion Europe SAS. Soliris is currently authorized for the treatment of paroxysmal nocturnal haemoglobinuria in adults only and atypical haemolytic uremic syndrome in adults and children. The CHMPís opinion now recommends that the PNH indication be extended to include children, the EMA announced.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 26, 2015
07:13 EDTALXNAlexion receives CHMP positive opinions for Strensiq, Kanuma in the EU
Subscribe for More Information
June 23, 2015
06:32 EDTALXNAlexion completes acquisition of Synageva
Subscribe for More Information
June 22, 2015
06:33 EDTALXNAlexion accepts shares of Synageva tendered into exchange offer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use